How First In Class Hepatitis B Approval At GSK (LSE:GSK) Has Changed Its Investment Story

yf_tkr_GSK · 2026-10-23 · Bullish AI sentiment

$GSK

GSK received FDA approval for Hibsago, an antisense oligonucleotide injection used with existing antiviral therapy to treat certain adults with chronic hepatitis B without cirrhosis, supported by phase III data showing functional cure in a subset of eligible patients. The product opens a new treatment category within GSK’s liver disease portfolio. It pairs a first in class mechanism with companion diagnostics and may reshape how clinicians manage long term HBV care for carefully selected...

Sector coverage: Healthcare · Drug Manufacturers - General

Read the original at yf_tkr_GSK ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.